Calistoga Pharmaceuticals
Seattle, Washington, United States
About Calistoga Pharmaceuticals
Calistoga Pharmaceuticals, Inc. is the leader in developing innovative oral medicines targeting selected isoforms of the PI3 kinase pathway to improve the health of patients with cancer and inflammatory diseases. The PI3K pathway is a critical cellular pathway involved in cell survival and immune cell activation. Calistoga Pharmaceuticals' small-molecule therapeutic candidates inhibit specific isoforms of the PI3K pathway, providing a targeted treatment approach designed to maximize clinical outcome and limit unwanted side effects. Calistoga Pharmaceuticals' lead product, CAL-101, an oral delta-isoform selective PI3K inhibitor, has demonstrated promising clinical responses in patients with B-cell malignancies and is currently being evaluated in multiple clinical trials. In addition to CAL-101, Calistoga Pharmaceuticals' product development pipeline includes other selective PI3K inhibitors in early preclinical development or ready for initial clinical trials in patients with cancer or inflammatory diseases.
Company Facts
- Operating status: Closed
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Total funding: $97.2M
- Funding stage: M&A
- Last round: Series C (Jun 2010)
- Website: calistogapharma.com
- Phone: 07804443213
Industries & Categories
Alternative Medicine, Biotechnology, Medical
Social Profiles
Canonical: https://fsome.com/organization/calistoga-pharmaceuticals-2578851 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.